• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Bayer Will Appeal India Compulsory Licence On Its Cancer Drug

05/03/2013 by Intellectual Property Watch 7 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

German pharmaceutical manufacturer Bayer has announced it will appeal yesterday’s ruling in India that upheld a compulsory licence on one of its drugs.

“We strongly disagree with the conclusions of the Intellectual Property Appellate Board,” Bayer said in a statement. “Bayer is committed to protecting its patents for Nexavar and will rigorously continue to defend our intellectual property rights within the Indian legal system. We will pursue the case in front of High Court in Mumbai with a writ petition.”

The IPAB ruled yesterday that the Indian government was within its rights in issuing a compulsory licence allowing the manufacture of affordable generic versions of Bayer’s patented drug, with royalties to be paid to Bayer (IPW, 4 March 2013).

Bayer argued that India’s problems of medicines access are due to poor services and infrastructure, not patents, and that the IPAB order “weakens the international patent system and endangers pharmaceutical research.” But it did not deny that the compulsory licence has led to a dramatic dropp in the price of the drug in question, Nexavar, putting it in reach of millions more people in India. But Bayer has had a programme in place since 2008 aimed at reducing the monthly cost of Nexavar for qualified persons, and said that 73 percent of all Nexavar patients were enrolled in the programme.

“The challenges faced by the Indian healthcare system have little or nothing to do with patents on pharmaceutical products as all products on India’s essential drug list are not patented,” Bayer said. “One of the main barriers to access to medicines in developing countries such as India is the lack of adequate healthcare services and infrastructure ensuring that drugs will effectively bring treatment to those who most need it.”

Bayer also described the importance of making medicines expensive in order to repay research and development costs. “The limited period of marketing exclusivity made possible by patents ensures that the costs associated with the research and development of innovative medicines can be recovered,” it said.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Bayer Will Appeal India Compulsory Licence On Its Cancer Drug" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Access to Knowledge/ Education, Asia/Pacific, Development, Enforcement, English, Health & IP, Human Rights, IP Law, Patents/Designs/Trade Secrets

Comments

  1. Drug Import Licence india says

    16/01/2014 at 5:16 pm

    it is really great suggestion for drug import license in india today every younger need to basically treatment of drug thanks for sharing us.

    Reply

Trackbacks

  1. India’s First Compulsory Licence Upheld, But Legal Fights Likely To Continue | Intellectual Property Watch says:
    05/03/2013 at 2:23 pm

    […] [Update: Bayer on 5 March announced it will appeal the decision (IPW, Developing Country Policy, 5 March 2013). […]

    Reply
  2. Bayer CEO: ‘We don’t make medicine for poor Indians’ | Anti-Imperialism.com says:
    02/02/2014 at 1:34 pm

    […] http://www.ip-watch.org/2013/03/05/bayer-will-appeal-india-compulsory-licence-on-its-cancer-drug/ […]

    Reply
  3. BAYER CEO: ‘WE DON’T MAKE MEDICINE FOR POOR INDIANS’ | Other Aspect says:
    02/02/2014 at 4:19 pm

    […] http://www.ip-watch.org/2013/03/05/bayer-will-appeal-india-compulsory-licence-on-its-cancer-drug/ […]

    Reply
  4. New cancer drug Nexavar not for Indians but western patients who afford #Bayer | AamJanata says:
    04/02/2014 at 8:22 am

    […] http://www.ip-watch.org/2013/03/05/bayer-will-appeal-india-compulsory-licence-on-its-cancer-drug/ […]

    Reply
  5. Bayer’s CEO: New Cancer Drugs Are Only For Western Patients, New Cancer Medicine for Rich People, Not Indians says:
    11/02/2014 at 2:41 pm

    […] http://www.ip-watch.org/2013/03/05/bayer-will-appeal-india-compulsory-licence-on-its-cancer-drug/ […]

    Reply
  6. Bayer’s CEO: New Cancer Drugs Are Only For Western Patients, New Cancer Medicine for Rich People, Not Indians - Live Free, Live Natural says:
    14/02/2014 at 3:50 pm

    […] http://www.ip-watch.org/2013/03/05/bayer-will-appeal-india-compulsory-licence-on-its-cancer-drug/ […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.